Invivyd Stock (NASDAQ:IVVD)
Previous Close
$1.14
52W Range
$0.81 - $5.20
50D Avg
$1.07
200D Avg
$2.52
Market Cap
$132.58M
Avg Vol (3M)
$635.35K
Beta
0.61
Div Yield
-
IVVD Company Profile
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
IVVD Performance
Peer Comparison
| Ticker | Company |
|---|---|
| MGTA | Dianthus Therapeutics, Inc. |
| ABEO | Abeona Therapeutics Inc. |
| APVO | Aptevo Therapeutics Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| ERAS | Erasca, Inc. |
| RGNX | REGENXBIO Inc. |
| GBIO | Generation Bio Co. |
| BDTX | Black Diamond Therapeutics, Inc. |
| RXRX | Recursion Pharmaceuticals, Inc. |
| UBX | Unity Biotechnology, Inc. |
| KRON | Kronos Bio, Inc. |
| PASG | Passage Bio, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| AVIR | Atea Pharmaceuticals, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| EXAI | Exscientia plc |